PT3123381T - Composições e métodos relacionados com o diagnóstico de cancro da próstata - Google Patents

Composições e métodos relacionados com o diagnóstico de cancro da próstata

Info

Publication number
PT3123381T
PT3123381T PT157687351T PT15768735T PT3123381T PT 3123381 T PT3123381 T PT 3123381T PT 157687351 T PT157687351 T PT 157687351T PT 15768735 T PT15768735 T PT 15768735T PT 3123381 T PT3123381 T PT 3123381T
Authority
PT
Portugal
Prior art keywords
diagnosis
compositions
prostate cancer
methods related
methods
Prior art date
Application number
PT157687351T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of PT3123381T publication Critical patent/PT3123381T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
PT157687351T 2014-03-28 2015-03-27 Composições e métodos relacionados com o diagnóstico de cancro da próstata PT3123381T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
PT3123381T true PT3123381T (pt) 2023-12-22

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157687351T PT3123381T (pt) 2014-03-28 2015-03-27 Composições e métodos relacionados com o diagnóstico de cancro da próstata

Country Status (24)

Country Link
US (2) US11761962B2 (enExample)
EP (2) EP3299977A1 (enExample)
JP (3) JP6775488B2 (enExample)
KR (1) KR102505543B1 (enExample)
CN (2) CN106663149A (enExample)
AR (1) AR099883A1 (enExample)
AU (1) AU2015237270B2 (enExample)
CA (1) CA2944001C (enExample)
CL (1) CL2016002419A1 (enExample)
DE (1) DE202015009668U1 (enExample)
DK (1) DK3123381T3 (enExample)
EA (1) EA201691952A1 (enExample)
ES (1) ES2964706T3 (enExample)
FI (1) FI3123381T3 (enExample)
HU (1) HUE065029T2 (enExample)
IL (2) IL247981B (enExample)
MX (2) MX392384B (enExample)
MY (1) MY192513A (enExample)
PE (1) PE20170298A1 (enExample)
PL (1) PL3123381T3 (enExample)
PT (1) PT3123381T (enExample)
SG (2) SG10201808585TA (enExample)
TW (1) TWI687688B (enExample)
WO (1) WO2015148979A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
ES2978966T3 (es) 2012-03-05 2024-09-23 Oy Arctic Partners Ab Métodos y aparatos para predecir el riesgo de cáncer de próstata y el volumen de la glándula prostática
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DE202016008692U1 (de) 2015-03-27 2019-02-13 Opko Diagnostics, Llc Prostata-Antigen-Standards und deren Verwendung
IL258189B2 (en) * 2015-10-05 2023-03-01 Fredax Ab Antibodies from humans against prostate-specific antigen (5I.10)
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
EP3397387B1 (en) 2015-12-29 2021-03-24 Opko Diagnostics, LLC Fluid collection device and related methods
US20190355473A1 (en) * 2017-01-08 2019-11-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
EP4407631A3 (en) * 2019-10-11 2024-10-09 C The Signs Limited Diagnostic tool
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514B (zh) * 2024-08-08 2024-10-29 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
EP0725593B1 (en) 1993-10-28 2004-04-07 I-Stat Corporation Fluid sample collection and introduction device
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
KR19990036069A (ko) 1995-08-03 1999-05-25 이.에이치. 리링크 진단 장치
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
JP4495349B2 (ja) 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
CA2424941A1 (en) 2000-10-10 2002-04-18 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
EP1390523B1 (en) 2000-11-20 2007-05-09 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
US20040219163A1 (en) 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
EP1461606A4 (en) 2001-12-05 2005-06-29 Univ Washington MICROFLUIDIC DEVICE AND SURFACE DECORATION PROCESS FOR SOLID PHASE AFFINITY BINDING ASSAYS
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
ATE468534T1 (de) 2002-08-06 2010-06-15 Univ Johns Hopkins Verwendung von biomarkern zum nachweis von eierstockkrebs
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
EP1691924B1 (en) 2003-12-10 2016-09-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A modular biochip assembly
EP1704405A1 (en) 2003-12-31 2006-09-27 The President and Fellows of Harvard College Assay device and method
EP2523004B1 (en) 2004-01-26 2020-05-20 President and Fellows of Harvard College Method of determining a sample component and immunoassay
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
CA2564208A1 (en) 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
AU2005278136A1 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
EP1802764A4 (en) 2004-09-17 2010-02-03 Univ Johns Hopkins BIOMARKER FOR BREAST CANCER
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
BRPI0709176A2 (pt) 2006-03-24 2011-06-28 Phenomenome Discoveries Inc biomarcadores úteis para diagnosticar o cáncer de próstata e seus métodos
AU2007271232A1 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
WO2008079095A1 (en) 2006-12-22 2008-07-03 Phadia Ab Novel prostate kallikrein allergen
ES2687620T3 (es) 2007-05-04 2018-10-26 Opko Diagnostics, Llc Dispositivo y método para análisis en sistemas microfluídicos
CN101918836B (zh) * 2007-05-08 2014-04-30 皮可贝拉有限责任公司 诊断和治疗前列腺癌和肺癌的方法
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
ES2543985T3 (es) 2007-10-22 2015-08-26 St Vincent's Hospital Sydney Limited Métodos de pronóstico
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
EP2344890B1 (en) 2008-10-20 2021-08-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
US20100168621A1 (en) 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
MX2011011571A (es) 2009-05-01 2012-02-13 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
ES2516866T3 (es) 2009-06-04 2014-10-31 Metanomics Health Gmbh Medios y métodos para el diagnóstico de carcinomas de próstata
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
WO2011130625A1 (en) 2010-04-16 2011-10-20 Claros Diagnostics, Inc. Feedback control in microfluidic systems
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
US9638706B2 (en) 2011-07-21 2017-05-02 Wako Pure Chemical Industries, Ltd. Standard solution for use in analysis of amino acid in plasma
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
WO2013106778A2 (en) 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
ES2978966T3 (es) 2012-03-05 2024-09-23 Oy Arctic Partners Ab Métodos y aparatos para predecir el riesgo de cáncer de próstata y el volumen de la glándula prostática
US20150094221A1 (en) 2012-05-16 2015-04-02 Phadia Ab Method for Indicating the Presence or Non-Presence of Prostate Cancer
EA201492284A1 (ru) 2012-06-27 2015-11-30 Берг Ллк Применение маркеров в диагностике и лечении рака предстательной железы
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
JP2016503301A (ja) 2012-11-20 2016-02-04 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 侵攻性前立腺癌の存在または不存在を判定する方法
AU2013349721B2 (en) 2012-11-20 2019-03-28 A3P Biomedical Ab Prognostic method for individuals with prostate cancer
KR102894975B1 (ko) 2013-11-19 2025-12-04 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
WO2015137870A1 (en) 2014-03-11 2015-09-17 Phadia Ab Method for detecting a solid tumor cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3268978A1 (en) 2015-03-12 2018-01-17 Thermo Finnigan LLC Methods for data-dependent mass spectrometry of mixed biomolecular analytes
DE202016008692U1 (de) 2015-03-27 2019-02-13 Opko Diagnostics, Llc Prostata-Antigen-Standards und deren Verwendung
HK1247824A1 (zh) 2015-04-29 2018-10-05 欧普科诊断有限责任公司 用於主动监控前列腺癌的组合物和方法
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
US20210208146A1 (en) 2018-05-16 2021-07-08 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
US20160025732A1 (en) 2016-01-28
CN114740202A (zh) 2022-07-12
EP3299977A1 (en) 2018-03-28
EP3123381A4 (en) 2018-02-21
AU2015237270B2 (en) 2021-09-09
CL2016002419A1 (es) 2017-03-31
KR102505543B1 (ko) 2023-03-02
WO2015148979A8 (en) 2016-01-07
US20230393137A1 (en) 2023-12-07
HUE065029T2 (hu) 2024-04-28
EP3123381A1 (en) 2017-02-01
WO2015148979A1 (en) 2015-10-01
JP7256781B2 (ja) 2023-04-12
IL280039B (en) 2021-12-01
EA201691952A1 (ru) 2017-05-31
MX2016012667A (es) 2017-01-09
JP2023017841A (ja) 2023-02-07
CN106663149A (zh) 2017-05-10
KR20170008729A (ko) 2017-01-24
TW201621320A (zh) 2016-06-16
IL247981A0 (en) 2016-11-30
PL3123381T3 (pl) 2024-02-26
SG11201608035UA (en) 2016-10-28
CA2944001C (en) 2023-08-15
SG10201808585TA (en) 2018-11-29
IL247981B (en) 2021-02-28
IL280039A (en) 2021-03-01
ES2964706T3 (es) 2024-04-09
JP2017515127A (ja) 2017-06-08
DE202015009668U1 (de) 2019-01-21
BR112016022407A2 (pt) 2017-12-12
CA2944001A1 (en) 2015-10-01
US11761962B2 (en) 2023-09-19
AR099883A1 (es) 2016-08-24
AU2015237270A1 (en) 2016-10-20
EP3123381B1 (en) 2023-10-11
TWI687688B (zh) 2020-03-11
MX2022002365A (es) 2022-04-06
DK3123381T3 (da) 2023-11-27
MX392384B (es) 2025-03-24
FI3123381T3 (fi) 2023-11-27
PE20170298A1 (es) 2017-04-18
MY192513A (en) 2022-08-24
JP6775488B2 (ja) 2020-10-28
JP2021009157A (ja) 2021-01-28
JP7506131B2 (ja) 2024-06-25

Similar Documents

Publication Publication Date Title
IL280039B (en) Compositions and methods related to diagnosis of prostate cancer
IL273090B (en) Methods and preparations for the treatment of cancer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3294770T4 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
FR3021533B1 (fr) Composition cosmetique de type gel
HUE059694T2 (hu) Készítmény rák kezelésére
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
EP3186393A4 (en) Methods and compositions related to prostate cancer therapeutics
PT3223827T (pt) Composição de fibras alimentares
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
IL251903A0 (en) Apilimod for use in the treatment of colorectal cancer
HUE040167T2 (hu) Rákkezelés
PT3137479T (pt) Composições de oligonucleótidos e métodos de fabrico das mesmas
SG11201701076TA (en) Diagnosis of cancer
HRP20200128T1 (hr) Pripreme za liječenje gd2 pozitivnog raka
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
BR112016015641A8 (pt) composições e métodos de tratamento de condições patológicas inflamatórias da pele usando alantoína.
DK3233104T3 (da) Immunterapi-behandlinger og -sammensætninger
FR3025098B1 (fr) Composition cosmetique de type gel facilement demaquillable
FR3022461B1 (fr) Methodes therapeutiques et compositions
TH1501005132A (th) องค์ประกอบ และวิธีการสำหรับการวินิจฉัย และการรักษามะเร็งตับ